Abstract: The present invention provides for 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane and a pharmaceutically acceptable anion thereof for use in the topical treatment or prophylaxis of excessive sweating, and compositions containing these ingredients.

Abstract: Proposed is a drug containing (a) at least one compound of Formula (I) provided that R1 denotes H or CH3 and R2 denotes H or COOH, or salts thereof, and (b) at least one UV protection factor for the inhibition of MMP-1 expression induced by UV radiation.

Abstract: Disclosed is a stable gel comprising a gel matrix comprising polyethylene glycol and surface treated silica, wherein the gel matrix is formed with the polyethylene glycol and surface treated silica, and particulate sugar dispersed throughout the gel matrix, wherein the gel has less than 5 wt. % oil.

Abstract: The invention relates to a ternary lipid association of ?-sitosterol, isocetyl stearoyl stearate and glyceryl tri-2-ethylhexanoate, wherein the ?-sitosterol content of said association is between 0.1% and 5 wt. %.

Abstract: Provided are a deodorant composition that can dramatically improve the remaining performance of a bactericide on an application object after application and a deodorant product comprising the deodorant composition. The deodorant composition according to the present invention comprises ethanol, a bactericide, a hydrophobized hydroxyalkyl cellulose, and an ester compound having a molecular weight of 150 or more; and the deodorant product according to the present invention comprises a container and the deodorant composition filled in the container.

Abstract: The present invention relates to a process for making a consumer goods product comprising a benefit delivery composition, wherein the process comprises the steps of: (a) contacting a surfactant and a fatty amphiphile to form a lamellar phase composition; (b) contacting the lamellar phase composition with silicone to form the benefit delivery composition, (c) contacting the benefit delivery composition with at least three different consumer goods products ingredients to form a consumer goods product, wherein the fatty amphiphile has a melting point of at least 40° C., wherein in step (a) the fatty amphiphile is at a temperature above its melting point when it is contacted with the surfactant, wherein the fatty amphiphile is subsequently cooled to a temperature below its melting point, wherein the benefit delivery composition comprises greater than 10 wt % silicone, and wherein the fatty amphiphile is selected from fatty acid, fatty alcohol and mixtures thereof.

Abstract: The present invention relates to a process for making a benefit delivery composition, wherein the process comprises the steps of: (a) contacting a surfactant and a fatty amphiphile to form a lamellar phase composition; (b) contacting a silicone and perfume to form a premix composition; (c) contacting the lamellar phase composition and the premix composition to form the benefit delivery composition, (d) contacting the benefit delivery composition with at least three different consumer goods product ingredients to form a consumer goods product, wherein the fatty amphiphile has a melting point of at least 40° C., wherein in step (a) the fatty amphiphile is at a temperature above its melting point when it is contacted with the surfactant, wherein the fatty amphiphile is subsequently cooled to a temperature below its melting point, and wherein the fatty amphiphile is selected from fatty acid, fatty alcohol and mixtures thereof.

Abstract: The invention is directed to a cosmetic which comprises an ionic silicone as described herein.

Abstract: The invention is directed to a personal care composition which contains a crosslinked ionic silicone network wherein the crosslinked ionic silicone network is formed by the ring-opening polymerization of oxirane moiety.

Abstract: A non-whitening sunscreen formulation for application to wet skin includes a surfactant system and organic UV absorbing materials where surfactant system includes a silicon based surfactant and a nonionic Gemini surfactant. Methods of making the sunscreen formulation are also included.

Abstract: The invention is directed to a personal care composition which contains an ionically-modified cross-linked silicone network which is formed by the polymerization of a silicone polymer containing hydrosilylation effective unsaturated moiety, silyl hydride moiety and ionic radicals.

Abstract: This application discloses oral care compositions comprising cannabinoids, preferably cannabidiol and/or cannabigerol. The oral care composition disclosed in this application may be a tooth paste, a tooth powder, or a mouthwash solution. The oral care composition may be used to treat oral infectious disease, including periimplantitis, periodontitis, oral mucositis, and dental pain.

Abstract: Disclosed is a method for moisturizing skin or treating fine lines or wrinkles, the method comprising topically applying to skin in need thereof a composition comprising pomegranate extract that includes pomegranate sterols, and shale extract that includes water-soluble minerals, wherein topical application of the composition to the skin in need thereof moisturizes the skin or treats fine lines or wrinkles.

Abstract: The invention is an invention belonging to the field of hair growth promoters and hair tonics. More, particularly, it relates to hair tonic composition for producing hair growth as well as uses related to thereto. The novel hair tonic composition comprises plant hormones like Gibberellins, Abscisic acid, Indolebutyric acid and Lentinan with a carrier thereof. The present invention is specifically utilized in the pharmaceutical or cosmetic fields.

Abstract: Compositions for use in oral hygiene contain a Lactobacillus helveticus strain. Compositions further containing a Lactobacillus plantarum strain, especially Lactobacillus plantarum SD5870, are particularly effective. The combination of Lactobacillus helveticus LAFTI L10 and Lactobacillus plantarum SD5870 synergistically improves oral hygiene. The compositions are particularly useful against dental caries.

Abstract: An apparatus configured to provide a beneficial biological effect for a subject, and/or a method of treating the subject using the apparatus. The apparatus may be configured to trigger and maintain the elevation of Glutathione levels within the subject. The apparatus may rely on a non-invasive mechanism to elevate Glutathione levels in the subject. The apparatus may not require a traditional power source such as a battery or wall plug in order to be effective in elevating Glutathione levels in the subject. To trigger and maintain the elevation of Glutathione levels within the subject, the apparatus may transmit communication to the body of the subject that results in increased levels of Glutathione within the subject.

Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

Abstract: Materials and methods for treating a patient, optionally a patient with an eye disease, comprising providing a collection of particles that comprise a first biodegradable material that is a hydrogel or a xerogel and a therapeutic agent, with the first material, before biodegradation, having a rate of release for the therapeutic agent as measured in physiological solution, and forming a second hydrogel ex vivo or in situ on a tissue of the patient at a site of intended use, optionally at or near an eye, that at least partially coats the collection of particles. The agent is released to treat the patient.

Abstract: A method of treating a patient for an upper or lower respiratory tract infection includes mixing a dry powder pharmaceutical composition including tobramycin with a base liquid to produce a nebulizer solution dosage form. The method may further include encapsulating the powder in a capsule and dispensing the capsule for the subsequent mixing of the powder with the base prior to administration to the patient via intranasal nebulization.

Abstract: A method is provided for improving lung function in COPD by administering a muscarinic antagonist with a high efficiency nebulizer.

Abstract: Provided are nanoemulsion formulations useful for the delivery of hydrophobic platinum chemotherapeutic drugs to cancer patients, as well as methods of their preparation and use.

Abstract: There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.

Abstract: siRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.

Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and for water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.

Abstract: The invention relates to a coating composition for application to a veterinary pharmaceutical composition for oral administration, by a film coating method, comprising a powder appetising material a binder and a solvent. The invention further relates to a coating method by film coating of a solid veterinary pharmaceutical for oral administration and appetising medicaments for animals comprising a veterinary pharmaceutical composition and an appetising coating arranged around said composition, comprising an appetising material and a binder.

Abstract: Using porous hollow fiber membranes, systems/methods for continuously synthesizing polymer-coated particles by anti-solvent crystallization are provided. The disclosed systems/methods provide for synthesis of polymer-coated drug particles/crystals from solutions of the polymer and the drug particles in suspension by exposing the solution to an anti-solvent through a porous hollow fiber device. A feed solution of a coating polymer with suspended drug particles can be exposed to an anti-solvent through hollow fiber pores, thereby causing the polymer to precipitate on and coat the drug particles. In addition, a feed solution of a coating polymer with drug in solution can be exposed to an anti-solvent through hollow fiber pores, thereby causing the drug to crystallize from the solution and the polymer to precipitate/coat the drug. Results indicate that a uniformly coated, free-flowing product may be developed in this advantageous porous hollow fiber anti-solvent crystallization method.

Abstract: The present disclosure provides methods and compositions related to nanoparticles comprising an encapsulated hydrophobic drug. The methods described herein provide nanoparticles having a small size and a narrow size distribution.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The invention provides novel curcuminoid formulations which have improved aqueous solubility and bioavailability when compared to known curcuminoid dosage forms. Formulations of the invention exhibit an enhanced intestinal absorption of curcuminoids, a slower curcuminoid metabolism and a reduced rate of systemic curcuminoid elimination. Additionally, upon administration in vivo, the formulations described and claimed herein produce a high, sustained level of the curcuminoid metabolite tetrahydrocurcumin. For example, at about eight to about ten hours after oral administration to a human, tetrahydrocurcumin plasma levels of between about 50 ng/mL to about 175 ng/mL are detectable, even when that metabolite is absent from the administered formulation. Novel processes for making curcuminoid formulations which have improved aqueous solubility and oral bioavailability, and methods of treating a wide variety of inflammatory, immune and neurogenerative disorders and cancers, are also provided.

Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.

Abstract: Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.

Abstract: A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.

Abstract: The technology described herein is directed to methods of treating, e.g., obesity and/or asthma which relate to the interacting roles of Chi3L1 and Sirt1 in controlling adipose tissue and respiratory health.

Abstract: Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described.

Abstract: The present invention provides for methods and compositions for treating medium chain acyl-CoA dehydrogenase deficiency. It is based, at least in part, on the discovery that phenylbutyrate can serve as a substrate for medium chain acyl-CoA dehydrogenase. In non-limiting embodiments, phenylbutyrate and/or another source of phenylacetate is administered as a chaperone treatment to patients suffering from medium chain acyl-CoA dehydrogenase deficiency.

Abstract: Topical pharmaceutical gel compositions of diclofenac sodium are provided. The topical gel compositions contain at least about 10% w/w diclofenac sodium and are suitable for once-a-day topical application.

Abstract: A topical pharmaceutical gel composition of diclofenac sodium suitable for once-a-day topical application is provided. The topical gel composition contains at least about 10% w/w of diclofenac sodium and once-a-day application of the composition provides relief from pain or inflammation comparable to that achieved with four times daily application of diclofenac sodium 1% or 3% topical gel.

Abstract: Compositions and methods for inhibiting, treating, and/or preventing fatty acid metabolism disorders, particularly fatty acid oxidation disorders, in a subject are provided.

Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.

Abstract: A composition for use in developing and/or improving brain function comprises a glyceride having a palmitoyl group at the 2-position wherein at least 40% by weight of the palmitic acid content of the composition is present as palmitoyl groups bonded at the 2-position of a glyceride.

Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Abstract: The instant invention relates to pharmaceutical compositions comprising cathespin K inhibitors and Vitamin D.

Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.

Abstract: The invention generally relates to methods of treating a patient having, and/or at risk of, cardiovascular or cerebrovascular disorders. Such methods may include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.

Abstract: This disclosure relates to the field of angiogenesis, more particularly to the field of pathological angiogenesis. In particular, the disclosure has found that inhibitors reducing the activity of the enzyme carnitine palmitoyltransferase 1A can be used for treatment of diseases in which pathological angiogenesis is involved. In particular, the disclosure provides siRNAs directed against carnitine palmitoyltransferase 1A for the treatment of pathological angiogenesis. The disclosure also provides the use of a therapeutically effective amount of inhibitors of carnitine palmitoyltransferase 1A, or a pharmaceutically acceptable salt thereof, for the treatment of pathological angiogenesis.

Abstract: The present invention relates to synergistic compositions for protection against oxidative damage, consisting essentially of antacids in conjunction with antioxidants. The invention further relates to method for preventing oxidative damage using the compositions of the invention.

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Abstract: The present invention provides methods to reduce the number and severity of hot flashes utilizing tocotrienols. In particular, symptoms of perimenopause and menopause may be treated using the present methods. The present invention also provides methods to increase tissue concentrations of tocotrienols.

Abstract: Pharmaceutical compositions and methods of inhibiting tumor cell proliferation of triple-negative (ER?/PR?/HER2?) breast cancer cells and for treating subjects with a form of breast cancer having a triple-negative (ER?/PR?/HER2?) phenotype are provided. The methods include a step of contacting triple-negative breast cancer cells with an effective amount of a composition including Eribulin and CYC065.